Browsing Tag
Moderna
31 posts
Moderna faces fresh mRNA patent assault from CureVac as BioNTech tightens legal grip on COVID-19 vaccine royalties
Moderna just settled $950 million in mRNA litigation. Now BioNTech-owned CureVac wants Spikevax royalties too. The patent war is widening.
GSK wins FDA approval to extend Arexvy RSV vaccine to at-risk adults aged 18 to 49, opening 21 million-strong US market
FDA expands Arexvy approval to at-risk adults 18-49, opening 21M-strong US market. Read what this means for GSK, Pfizer, Moderna, and the RSV vaccine landscape.
Moderna shakes up leadership as COVID vaccine demand wanes—can new R&D head realign its future?
Find out why Moderna, Inc. is replacing its medical chief with a development leader and what it means for the company’s post-COVID pipeline strategy.
Five-year data boosts Moderna and Merck’s neoantigen vaccine strategy in adjuvant melanoma
Moderna and Merck reveal 5-year data showing 49% reduction in melanoma recurrence with their mRNA-4157 and KEYTRUDA combo. Read more on what’s next.
Why Merck’s MSD is paying up to $600m for Evaxion’s undisclosed vaccine candidate EVX-B3
MSD licenses Evaxion’s AI-discovered vaccine EVX-B3 with $7.5M upfront and up to $592M in milestones—why this risky biotech bet could redefine vaccines.
What happened to Moderna’s combo COVID–flu–RSV vaccine—and is it still in the race for 2026?
Moderna’s combo COVID–flu vaccine has been delayed to 2026 after FDA feedback. Find out what caused the setback and whether the mRNA-1083 shot can still launch next year.
NB.1.8.1 variant triggers global COVID-19 surge amid endemic transition
NB.1.8.1 variant drives global COVID-19 surge; China, Australia report highest transmission. WHO classifies risk as low but urges continued vaccine surveillance.
JN.1 variant: Why it still dominates global COVID-19 cases in mid-2025
JN.1 remains the most dominant COVID-19 variant in mid-2025. Explore why it still leads global cases, what WHO and CDC recommend, and how vaccines are adapting.
Fall 2025 COVID booster update: FDA endorses JN.1-based vaccine as dominant LP.8.1 strain spreads
FDA backs fall 2025 COVID booster targeting LP.8.1; rollout to begin by August. New vaccine expected to offer stronger protection against dominant variants.
Sarepta, Palantir, Moderna lead Wall Street declines as biotech, tech stocks tumble
U.S. stock market losers on May 6, 2025: Find out why Sarepta, Palantir, Moderna, Lattice Semiconductor and more saw sharp stock price drops.